Table 3. Treatment-related adverse events experienced by eight or more patients, and all grade 3/4 events reported following treatment with ridaforolimus.
| |
Ridaforolimus (N=45) |
|
|---|---|---|
| Adverse event, n (%)a | All grades | Grade 3/4 |
| Mouth soresb |
25 (56) |
4 (9) |
| Anaemia |
19 (42) |
10 (22) |
| Fatigue |
18 (40) |
2 (4) |
| Diarrhoea |
14 (31) |
0 |
| Nausea |
13 (29) |
2 (4) |
| Vomiting |
12 (27) |
1 (2) |
| Asthenia |
11 (24) |
2 (4) |
| Anorexia |
10 (22) |
1 (2) |
| Dysgeusia |
8 (18) |
0 |
| Anorexia |
10 (22) |
1 (2) |
| Hyperglycaemia |
5 (11) |
4 (9) |
| Hypertriglyceridaemia |
5 (11) |
2 (4) |
| Hypokalaemia | 5 (11) | 1 (2) |
a
If multiple episodes of an event are experienced by one patient, the patient/event is presented once at the highest grade reported.
b
Includes stomatitis and mucosal inflammation.